Merck & Co., Inc.
NYSEMRK enters the week with its most defensive options positioning of the past year, even as the Street continues to raise targets — a split that puts the market and analysts squarely at odds. The options signal is the sharpest data point this week. The put/call ratio jumped to 0.91 on Tuesday, nearly three standard deviations above its 20-day average of 0.74 — the highest reading of…
MRK RBC Capital downgrades to Sector Perform, raises PT to $150 (5.6% above current), amid broader analyst re-rating cycle; stock at $148.99, up 19.8% YTD despite post-Q2 headwinds.
A new long-form analysis for MRK this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumMRK enters the week with its most defensive options positioning of the past year, even as the Street continues to raise targets — a split that puts the market and analysts squarely at odds. The options signal is the…
Snapshot as of 20 Sept 2026
Merck & Co. closed Tuesday at $156.45, up nearly 16% on the week, and now trades above every analyst price target except the outlier calls — a position that raises a clean question about what drives the next leg. The…
Options positioning on Merck & Co. just flashed its most bearish read in three weeks. The put/call ratio hit 0.8468 on August 21 — 3.2 standard deviations above the 20-day mean of 0.763. That's the loudest options…
Merck & Co. has pulled back fractionally from its recent 12-month high, and the week's tension is straightforward: analysts keep lifting targets while insiders keep cashing out into every uptick. The stock closed at…
Merck & Co. has recovered from its post-earnings dip and is now trading at a fresh recent high — the interesting story this week is not the short book, which remains negligible, but an accelerating wave of analyst…
Merck & Co. has given back some of its pre-earnings gains, slipping 2.9% on the week to $128.00 after Q2 results landed on August 4 — a muted post-print reaction that leaves the stock roughly $8 below where the most…
Merck & Co. heads into Tuesday's Q2 earnings call with the Street's bullish revision cycle still running, short sellers largely gone, and peers under pressure — leaving the stock to stand on its fundamentals alone. The…
Merck & Co. enters its August 4 Q2 earnings call with Barclays lifting its target to $150 that same morning — the most bullish Street action yet in a month of relentless upward revisions. The analyst tide has been…
Merck & Co. has given back ground sharply this week, falling 6.3% to $120.78 — yet analysts responded by raising price targets, not cutting them, creating the clearest tension in the MRK story right now. The stock's…
Merck & Co. is consolidating around the Street consensus after a strong month, with Wells Fargo lifting its target today and options traders remaining more bullish than their recent habit. The most active data point…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRK — free to start on ORTEX.
Sign up for free →Open MRK on ORTEX